4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions

Alzheimer's Association International Conference 2026

July 12-15, 2026 | London, United Kingdom, and Online

2014

Advancements In Target Discovery, Biomarker Development, And Therapeutic Strategies Through Public-private Partnerships

View Poster Contact Presenter

Poster Presenter

Francesca Cignarella

Authors

Francesca Cignarella

Affiliations

null

Part of Topic

Foundation for the National Institutes of Health Building Bridges to Breakthroughs www.fnih.org

Science has the power to cure, but no single organization can do it alone. We partner with world-class organizations to tackle the most pressing health challenges.

FNIH has managed AD projects totaling over half a billion dollars

FNIH has a long legacy of impactful work in Alzheimer’s:

Plasma Aß project has produced numerous scientific impacts

Imaging AD biomarker - SV2A

AD Biosignature is the next phase of BBMx work

AMP AD: Transforming Alzheimer’s research through open science

§Generated rich, human, multiomic data, which has been made available to >3000 users to date (60% academia / 40% industry)

§Established new mechanistic disease insights on role of the genome, proteome, metabolome, and microbiome

§Increased the availability of molecular network models of disease pathways

§Developed phenotype animal models and evaluated them relative to human molecular networks

§Identified and ranked 900+ unique targets, and made them available through the Agora Platform, along with supporting evidence and extensive druggability information

§Confirmed the utility of Tau PET imaging for tracking responsiveness to treatment and disease progression

§Data and biosamples from the A4 study are now available for download and exploration

Advancements In Target Discovery, Biomarker Development, And Therapeutic Strategies Through Public-private Partnerships

Poster Presenter

Authors

Affiliations

Part of Topic

Comments